Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Finished Goods (2017 - 2024)

Historic Finished Goods for China Pharma Holdings (CPHI) over the last 8 years, with Q3 2024 value amounting to $1.3 million.

  • China Pharma Holdings' Finished Goods rose 683.12% to $1.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.3 million, marking a year-over-year increase of 683.12%. This contributed to the annual value of $1.5 million for FY2023, which is 16673.45% up from last year.
  • As of Q3 2024, China Pharma Holdings' Finished Goods stood at $1.3 million, which was up 683.12% from $1.5 million recorded in Q2 2024.
  • In the past 5 years, China Pharma Holdings' Finished Goods registered a high of $1.7 million during Q1 2024, and its lowest value of $551000.0 during Q4 2021.
  • Moreover, its 5-year median value for Finished Goods was $1.3 million (2022), whereas its average is $1.2 million.
  • As far as peak fluctuations go, China Pharma Holdings' Finished Goods plummeted by 4599.68% in 2021, and later skyrocketed by 16673.45% in 2023.
  • China Pharma Holdings' Finished Goods (Quarter) stood at $960375.0 in 2020, then crashed by 42.63% to $551000.0 in 2021, then changed by 0.0% to $551000.0 in 2022, then soared by 166.73% to $1.5 million in 2023, then dropped by 11.91% to $1.3 million in 2024.
  • Its Finished Goods was $1.3 million in Q3 2024, compared to $1.5 million in Q2 2024 and $1.7 million in Q1 2024.